Leo Pharma wants to be first in US with hand eczema treatment

After securing fast-track status from the FDA, Leo Pharma hopes to become the first company in the US to specifically address chronic hand eczema, for which there is no treatment in the country.
Photo: Leo Pharma / PR
Photo: Leo Pharma / PR
BY ELIZABETH MØNSTED JOHANSEN, translated by Jonas Sahl Jørgensen

In many ways, Leo Pharma is headed into unknown territory after the firm secured fast-track status for its drug candidate delgocitinib from the US Food and Drug Administration, FDA.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading